Cargando…
Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas
HSP90 is critical for maintenance of the cellular proteostasis. In cancer cells, HSP90 also becomes a nucleating site for the stabilization of multiprotein complexes including signaling pathways and transcription complexes. Here we described the role of this HSP90 form, referred to as oncogenic HSP9...
Autores principales: | Calvo-Vidal, M. Nieves, Zamponi, Nahuel, Krumsiek, Jan, Stockslager, Max A., Revuelta, Maria V., Phillip, Jude M., Marullo, Rossella, Tikhonova, Ekaterina, Kotlov, Nikita, Patel, Jayeshkumar, Yang, Shao Ning, Yang, Lucy, Taldone, Tony, Thieblemont, Catherine, Leonard, John P., Martin, Peter, Inghirami, Giorgio, Chiosis, Gabriela, Manalis, Scott R., Cerchietti, Leandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530929/ https://www.ncbi.nlm.nih.gov/pubmed/34479963 http://dx.doi.org/10.1158/0008-5472.CAN-21-2734 |
Ejemplares similares
-
A Purine Analog Synergizes with Chloroquine (CQ) by Targeting Plasmodium falciparum Hsp90 (PfHsp90)
por: Shahinas, Dea, et al.
Publicado: (2013) -
Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway
por: Pera, Benet, et al.
Publicado: (2018) -
Assay Strategies for the Discovery and Validation of Therapeutics Targeting Brugia pahangi Hsp90
por: Taldone, Tony, et al.
Publicado: (2010) -
Hsp90 is a viable therapeutic target in the treatment of KSHV-associated primary effusion lymphoma
por: Nayar, Utthara, et al.
Publicado: (2010) -
The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1
por: Usmani, Saad Z, et al.
Publicado: (2010)